Researchers are revisiting a vaccine that could extend brain cancer survival by boosting patients’ immune systems to fight cancerous tumors. The vaccine had undergone a Phase I clinical trial in 2001 but was largely abandoned for lack of efficacy. Now, a new methodology is breathing life back into the treatment’s potential to extend the life of those who suffer from brain cancer. The team at Thomas Jefferson University is looking to administer the vaccine to patients before chemotherapy, so that their immune systems are less compromised and better able to be directed by the vaccine to attack tumors. Initial results of a more recent Phase I trial are more promising. Phase II trials are slated to begin in early 2015.
Please share your thoughts in the comments below!
Do you like what you see? Please help us reach a greater audience by liking and following us on Facebook: https://www.facebook.com/tenminuteyouth